IL6 and COVID-19: IL‐6 is an important therapeutic target, and IL‐6 blockers have been repurposed to treat cytokine storms in severe COVID‐19 patients [45], highlighting IL‐6 as a key pro‐inflammatory cytokine in the pathophysiology of COVID‐19 and its severe cases.